Table 1. Summary of clinical characteristics of discovery and validation cohorts.
| Characteristics | n (%) | |||
| Discovery cohort (N=782) | Validation cohort 1 (N=245) | Validation cohort 2 (N=1,291) | Validation cohort 3 (N=75) | |
| NA, not available; OS, overall survival; PFS, progression-free survival. | ||||
| Age [median (range)] (year) | 65 (18−92) | 56 (27−86) | 62 (15−90) | 59 (15−76) |
| Gender | ||||
| Female | 331 (42.3) | 46 (18.8) | 462 (35.8) | 21 (28.0) |
| Male | 451 (57.7) | 26 (10.6) | 829 (64.2) | 54 (72.0) |
| NA | 0 (0) | 173 (70.6) | 0 (0) | 0 (0) |
| Therapy | ||||
| Combination | 132 (16.9) | 20 (8.2) | 209 (16.2) | 0 (0) |
| Monotherapy | 650 (83.1) | 225 (91.8) | 1,082 (83.8) | 75 (100) |
| NA | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Treatment response | ||||
| Response | 226 (28.9) | 39 (15.9) | 0 (0) | 16 (21.3) |
| Non-response | 541 (69.2) | 133 (54.3) | 0 (0) | 59 (78.7) |
| NA | 15 (1.9) | 73 (29.8) | 1,291 (100) | 0 (0) |
| Treatment benefit | ||||
| Benefit | 315 (40.3) | 29 (11.8) | 0 (0) | NA |
| Non-benefit | 430 (55.0) | 103 (42.0) | 0 (0) | NA |
| NA | 37 (4.7) | 113 (46.1) | 1,291 (100) | NA |
| OS | ||||
| Recorded | 664 (84.9) | 139 (56.7) | 1,291 (100) | 75 (100) |
| Not recorded | 118 (15.1) | 106 (43.3) | 0 (0) | 0 (0) |
| PFS | ||||
| Recorded | 730 (93.4) | 132 (53.9) | 0 (0) | 74 (98.7) |
| Not recorded | 52 (6.6) | 113 (46.1) | 1,291 (100) | 1 (1.3) |
| Mutation status | ||||
| PTPRT uni-mut | 78 (10.0) | 12 (4.9) | 96 (7.4) | 4 (5.3) |
| PTPRD uni-mut | 77 (9.9) | 22 (9.0) | 67 (5.2) | 8 (10.7) |
| Co-mut | 37 (4.7) | 6 (2.4) | 48 (3.7) | 1 (1.3) |
| Wild | 590 (75.4) | 205 (83.7) | 1,080 (83.7) | 62 (82.7) |